Journal article
Metformin is Protective Against the Development of Mood Disorders
Pharmacopsychiatry, Vol.56(1), pp.25-31
2023
PMID: 36170869
Metrics
5 Record Views
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Abstract
Introduction: Mood disorders are a major cause of disability, and current treatment options are inadequate for reducing the burden on a global scale. The aim of this project was to identify drugs suitable for repurposing to treat mood disorders.
Methods: This mixed-method study utilized gene expression signature technology and pharmacoepidemiology to investigate drugs that may be suitable for repurposing to treat mood disorders.
Results: The transcriptional effects of a combination of drugs commonly used to treat mood disorders included regulation of the steroid and terpenoid backbone biosynthesis pathways, suggesting a mechanism involving cholesterol biosynthesis, and effects on the thyroid hormone signaling pathway. Connectivity Map analysis highlighted metformin, an FDA-approved treatment for type 2 diabetes, as a drug having global transcriptional effects similar to the mood disorder drug combination investigated. In a retrospective cohort study, we found evidence that metformin is protective against the onset of mood disorders.
Discussion: These results provide proof-of-principle of combining gene expression signature technology with pharmacoepidemiology to identify potential novel drugs for treating mood disorders. Importantly, metformin may have utility in the treatment of mood disorders, warranting future randomized controlled trials to test its efficacy.
Details
- Title
- Metformin is Protective Against the Development of Mood Disorders
- Creators
- Jacqueline Lake - Deakin University (Australia, Geelong)Chiara C Bortolasci - Deakin University (Australia, Geelong)Amanda L Stuart - Deakin University (Australia, Geelong)Julie A Pasco - Deakin University (Australia, Geelong)Srisaiyini Kidnapillai - Deakin University (Australia, Geelong)Briana Spolding - Deakin University (Australia, Geelong)Trang T T Truong - Deakin University (Australia, Geelong)Bruna Panizzutti - Deakin University (Australia, Geelong)Zoe S J Liu - Deakin University (Australia, Geelong)Olivia M Dean - Deakin University (Australia, Geelong)Tamsyn Crowley - Deakin University (Australia, Geelong)Mark Richardson - Deakin University (Australia, Geelong)Jee Hyun Kim - Deakin University (Australia, Geelong)Michael Berk - Deakin University (Australia, Geelong)Lana J Williams - Deakin University (Australia, Geelong)Ken Walder - Deakin University (Australia, Geelong)
- Publication Details
- Pharmacopsychiatry, Vol.56(1), pp.25-31
- Publisher
- Georg Thieme Verlag
- Grant note
- This research was funded by the National Health and Medical Research Council (NHMRC) Project Grant (1078928) and the Centre of Research Excellence (1153607).
- Identifiers
- 991013328728302368
- Copyright
- © 2022. Thieme.
- Academic Unit
- Office of Senior Deputy Vice Chancellor, Research
- Language
- English
- Resource Type
- Journal article